SALT LAKE CITY, UT--(Marketwire - June 08, 2009) - Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today the formation of an advisory board which will work closely with executive management to provide expertise and strategic guidance on potential partners the company identifies. Recently, Cancer Therapeutics announced that it had completed a definitive agreement with new partner, NanoTherapies, LLC.
“Our new advisory board will represent some of the most innovative professionals in our industry as well as others who will add tremendous experience which complement our new business model as we move forward,” said Chene Gardner, President and CEO of Cancer Therapeutics, Inc. “I am confident that their advice and guidance will be invaluable as we evaluate prospective partners, grow our company and create a footprint within the cancer treatment sector. Assembling an advisory board of this caliber is a key strategy in the ongoing development of Cancer Therapeutics.”
Gardner said he expects to make announcements of members to the newly formed board very soon.
About Cancer Therapeutics, Inc.:
Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in our pipeline.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words “estimate,” “anticipate,” “expect,” “believe,” and similar expressions are intended to be forward-looking statements.
Contact:
Investor Relations
David Donlin
Cervelle Group
Phone: 407-614-5959 ext. 223
